{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:41:58Z","timestamp":1768462918869,"version":"3.49.0"},"reference-count":323,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDP\/04501\/2020"],"award-info":[{"award-number":["UIDP\/04501\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["LA\/P\/0053\/2020"],"award-info":[{"award-number":["LA\/P\/0053\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDP\/04501\/2020"],"award-info":[{"award-number":["UIDP\/04501\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"Cardiovascular R&amp;D Center","award":["LA\/P\/0053\/2020"],"award-info":[{"award-number":["LA\/P\/0053\/2020"]}]},{"name":"RISE","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}]},{"name":"RISE","award":["UIDP\/04501\/2020"],"award-info":[{"award-number":["UIDP\/04501\/2020"]}]},{"name":"RISE","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}]},{"name":"RISE","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}]},{"name":"RISE","award":["LA\/P\/0053\/2020"],"award-info":[{"award-number":["LA\/P\/0053\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myotonic dystrophy type 1 (DM1) is a complex, multisystemic neuromuscular disorder with several pathological phenotypes, disease severities and ages of onset. DM1 presents significant challenges in clinical management due to its multisystemic nature, affecting multiple organs and systems beyond skeletal muscle. Tackling this condition requires a comprehensive approach that goes beyond symptom management, particularly considering the complexity of its manifestations and in the delayed diagnosis. In this review we will discuss the multisystem symptoms of DM1 and how this understanding is guiding the development of potential therapies for the improvement of patient outcomes and quality of life. This review aims to explore the available treatments and potential novel disease-modifying therapies targeting DM1 molecular mechanisms to address the broad multisystem symptoms of DM1. Effective strategies to manage symptoms remain crucial, such as physical therapy, medications for myotonia and diligent cardiac care. Metabolic management and hormonal therapies play crucial roles in addressing endocrine and metabolic abnormalities. Nevertheless, promising targeted therapies that include antisense oligonucleotides (ASOs) for RNA degradation, small molecules to disrupt protein-RNA interactions and gene editing offer a prospective approach to the underlying mechanisms of DM1 and improve patient outcomes across the different organ systems.<\/jats:p>","DOI":"10.3390\/ijms26115350","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:40:32Z","timestamp":1748864432000},"page":"5350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multisystem Symptoms in Myotonic Dystrophy Type 1: A Management and Therapeutic Perspective"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-8881","authenticated-orcid":false,"given":"Dhvani H.","family":"Kuntawala","sequence":"first","affiliation":[{"name":"Medical Sciences Department, Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-183 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-5805","authenticated-orcid":false,"given":"Rui","family":"Vitorino","sequence":"additional","affiliation":[{"name":"Medical Sciences Department, Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-183 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0123-1968","authenticated-orcid":false,"given":"Ana C.","family":"Cruz","sequence":"additional","affiliation":[{"name":"Medical Sciences Department, Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-183 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3277-1809","authenticated-orcid":false,"given":"Filipa","family":"Martins","sequence":"additional","affiliation":[{"name":"Medical Sciences Department, Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-183 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-5797","authenticated-orcid":false,"given":"Sandra","family":"Rebelo","sequence":"additional","affiliation":[{"name":"Medical Sciences Department, Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-183 Aveiro, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, H. (2014). Myotonic Dystrophy Type 1. Atlas of Genetic Diagnosis and Counseling, Springer.","DOI":"10.1007\/978-1-4614-6430-3_278-1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tibs.2004.03.006","article-title":"Advances in protein kinase B signalling: AKTion on multiple fronts","volume":"29","author":"Brazil","year":"2004","journal-title":"Trends Biochem. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.1546325","article-title":"Myotonic dystrophy mutation: An unstable CTG repeat in the 3\u2032 untranslated region of the gene","volume":"255","author":"Mahadevan","year":"1992","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11033-014-3791-4","article-title":"Altered nuclear structure in myotonic dystrophy type 1-derived fibroblasts","volume":"42","author":"Rodriguez","year":"2015","journal-title":"Mol. Biol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13023-019-1088-3","article-title":"The DM-scope registry: A rare disease innovative framework bridging the gap between research and medical care","volume":"14","author":"Dogan","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1017\/S0012162205000927","article-title":"Myotonic dystrophy: Muscle involvement in relation to disease type and size of expanded CTG-repeat sequence","volume":"47","author":"Kroksmark","year":"2005","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_8","unstructured":"Jaradeh, S. (2006). Muscle disorders affecting oral and pharyngeal swallowing. GI Motil. Online, Available online: https:\/\/www.nature.com\/gimo\/contents\/pt1\/full\/gimo35.html."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00415-013-6993-0","article-title":"Diagnostic odyssey of patients with myotonic dystrophy","volume":"260","author":"Hilbert","year":"2013","journal-title":"J. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000524734","article-title":"Global prevalence of myotonic dystrophy: An updated systematic review and meta-analysis","volume":"56","author":"Liao","year":"2022","journal-title":"Neuroepidemiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40900-023-00535-1","article-title":"Patient engagement in clinical trial design for rare neuromuscular disorders: Impact on the DELIVER and ACHIEVE clinical trials","volume":"10","author":"Furlong","year":"2024","journal-title":"Res. Involv. Engagem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1529-8027.2011.00313.x","article-title":"Peripheral neuropathy in myotonic dystrophy type 1","volume":"16","author":"Hermans","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Solbakken, G., L\u00f8seth, S., Frich, J.C., Dietrichs, E., and \u00d8rstavik, K. (2024). Small and large fiber neuropathy in adults with myotonic dystrophy type 1. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1375218"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1212\/01.WNL.0000144343.91136.CF","article-title":"Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1","volume":"63","author":"Bassez","year":"2004","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ahj.2003.08.008","article-title":"Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I","volume":"147","author":"Bhakta","year":"2004","journal-title":"Am. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Brunet Garcia, L., Hajra, A., Field, E., Wacher, J., Walsh, H., Norrish, G., Manzur, A., Muntoni, F., Munot, P., and Robb, S. (2022). Cardiac Manifestations of Myotonic Dystrophy in a Pediatric Cohort. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.910660"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1212\/01.wnl.0000208513.48550.08","article-title":"Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions","volume":"66","author":"Arsenault","year":"2006","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.nmd.2023.01.008","article-title":"Respiratory function and sleep in children with myotonic dystrophy type 1","volume":"33","author":"Cheminelle","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-510X(99)00042-8","article-title":"Excessive daytime sleepiness in myotonic dystrophy","volume":"164","author":"Giubilei","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CND.0b013e3181520095","article-title":"Myotonic Dystrophy Type 1 Presenting With Ventilatory Failure","volume":"9","author":"Souayah","year":"2007","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kuntawala, D.H., Martins, F., Vitorino, R., and Rebelo, S. (2023). Automatic Text-Mining Approach to Identify Molecular Target Candidates Associated with Metabolic Processes for Myotonic Dystrophy Type 1. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20032283"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.1212\/WNL.0000000000006948","article-title":"A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management","volume":"92","author":"Lagrue","year":"2019","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mus.20800","article-title":"Cerebral involvement in myotonic dystrophies","volume":"36","author":"Meola","year":"2007","journal-title":"Muscle Nerve Off. J. Am. Assoc. Electrodiagn. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejpn.2022.05.008","article-title":"Cognitive, neuropsychological and emotional-behavioural functioning in a sample of children with myotonic dystrophy type 1","volume":"39","author":"Ricci","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semerg.2022.01.013","article-title":"Alteraci\u00f3n cognitiva en la distrofia miot\u00f3nica tipo 1 (enfermedad de Steinert)","volume":"48","year":"2022","journal-title":"Med. Fam. SEMERGEN"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/acn3.50856","article-title":"Benign tumors in myotonic dystrophy type I target disease-related cancer sites","volume":"6","author":"Alsaggaf","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio, E.S., and Gonzalez-Perez, P. (2023). Cancer and Myotonic Dystrophy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051939"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1212\/WNL.0000000000003124","article-title":"Cancer risk in DM1 is sex-related and linked to miRNA-200\/141 downregulation","volume":"87","author":"Emparanza","year":"2016","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s10072-024-07527-3","article-title":"Myotonic dystrophy type 1 in South Korea: A comprehensive analysis of cancer and comorbidity risks","volume":"45","author":"Seo","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40981-021-00413-3","article-title":"Anesthetic management for a patient with myotonic dystrophy with remimazolam","volume":"7","author":"Morimoto","year":"2021","journal-title":"JA Clin. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289643","DOI":"10.1155\/2014\/289643","article-title":"Assessment of Premutation in Myotonic Dystrophy Type 1 Affected Family Members by TP-PCR and Genetic Counseling","volume":"2014","author":"Kumar","year":"2014","journal-title":"Case Rep. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1212\/WNL.56.3.328","article-title":"Frequency and stability of the myotonic dystrophy type 1 premutation","volume":"56","author":"Martorell","year":"2001","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Dogan, C., De Antonio, M., Hamroun, D., Varet, H., Fabbro, M., Rougier, F., Amarof, K., Arne Bes, M.-C., Bedat-Millet, A.-L., and Behin, A. (2016). Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: A nationwide multiple databases cross-sectional observational study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148264"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mateus, T., Martins, F., Nunes, A., Herdeiro, M.T., and Rebelo, S. (2021). Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18041794"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification","volume":"172","author":"Dogan","year":"2016","journal-title":"Rev. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5409\/wjcp.v4.i4.66","article-title":"Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions","volume":"4","author":"Ho","year":"2015","journal-title":"World J. Clin. Pediatr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1212\/CON.0000000000000793","article-title":"Myotonic muscular dystrophies","volume":"25","author":"Johnson","year":"2019","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nmd.2024.05.002","article-title":"Main features and disease outcome of congenital myotonic dystrophy\u2014Experience from a single tertiary center","volume":"40","author":"Meola","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jpeds.2012.12.070","article-title":"Congenital myotonic dystrophy: Canadian population-based surveillance study","volume":"163","author":"Campbell","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1469-8749.2012.04379.x","article-title":"Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1","volume":"54","author":"Douniol","year":"2012","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/B978-0-444-59565-2.00009-5","article-title":"Chapter 144\u2014Congenital and infantile myotonic dystrophy","volume":"Volume 113","author":"Dulac","year":"2013","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Peric, S., Pesovic, J., Savic-Pavicevic, D., Rakocevic Stojanovic, V., and Meola, G. (2022). Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010354"},{"key":"ref_44","unstructured":"Johnson, N.E., and Heatwole, C.R. (2012). Myotonic Dystrophy: From Bench to Bedside, Thieme Medical Publishers."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/mus.26716","article-title":"Clinical and genetic characteristics of childhood-onset myotonic dystrophy","volume":"60","author":"Stokes","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_46","unstructured":"Bird, T.D. (2021). Myotonic dystrophy type 1. GeneReviews, University of Washington."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hasuike, Y., Mochizuki, H., and Nakamori, M. (2022). Cellular Senescence and Aging in Myotonic Dystrophy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042339"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mateos-Aierdi, A.J., Goicoechea, M., Aiastui, A., Fern\u00e1ndez-Torr\u00f3n, R., Garcia-Puga, M., Matheu, A., and L\u00f3pez de Munain, A. (2015). Muscle wasting in myotonic dystrophies: A model of premature aging. Front. Aging Neurosci., 7.","DOI":"10.3389\/fnagi.2015.00125"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e30875","DOI":"10.1016\/j.heliyon.2024.e30875","article-title":"Neurocognitive disorder in Myotonic dystrophy type 1","volume":"10","author":"Winblad","year":"2024","journal-title":"Heliyon"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.gde.2017.01.007","article-title":"Myotonic dystrophy: Disease repeat range, penetrance, age of onset, and relationship between repeat size and phenotypes","volume":"44","author":"Yum","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejpn.2023.12.001","article-title":"Myotonic dystrophy type 1 (Steinert disease): 29 years of experience at a tertiary pediatric hospital","volume":"48","author":"Cascais","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/archdischild-2018-314837","article-title":"Myotonic dystrophy type 1: Clinical manifestations in children and adolescents","volume":"104","author":"Ho","year":"2019","journal-title":"Arch. Dis. Child."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ionova, S.A., Murtazina, A.F., Marakhonov, A.A., Shchagina, O.A., Ryadninskaya, N.V., Tebieva, I.S., Kadyshev, V.V., Borovikov, A.O., Ginter, E.K., and Kutsev, S.I. (2024). The Study of the Inheritance Mechanisms of Myotonic Dystrophy Type 1 (DM1) in Families from the Republic of North Ossetia-Alania. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179734"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s41431-020-0601-4","article-title":"Parental repeat length instability in myotonic dystrophy type 1 pre- and protomutations","volume":"28","author":"Joosten","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.nmd.2022.09.003","article-title":"Having an eye for myotonic dystrophy: A qualitative study on experiences and support needs in myotonic dystrophy type 1 patients with a diagnostic delay after early-onset cataract","volume":"32","author":"Karnebeek","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e208115","DOI":"10.1212\/WNL.0000000000208115","article-title":"Neurobehavioral Phenotype of Children With Congenital Myotonic Dystrophy","volume":"102","author":"Patel","year":"2024","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Soltanzadeh, P. (2022). Myotonic Dystrophies: A Genetic Overview. Genes, 13.","DOI":"10.3390\/genes13020367"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wu, Y., Wei, Q., Lin, J., Shang, H., and Ou, R. (2024). Cognitive impairment, neuroimaging abnormalities, and their correlations in myotonic dystrophy: A comprehensive review. Front. Cell. Neurosci., 18.","DOI":"10.3389\/fncel.2024.1369332"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1080\/15476286.2017.1279787","article-title":"Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat","volume":"14","author":"Gudde","year":"2017","journal-title":"RNA Biol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Izzo, M., Battistini, J., Provenzano, C., Martelli, F., Cardinali, B., and Falcone, G. (2022). Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094622"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Michel, L., Huguet-Lachon, A., and Gourdon, G. (2015). Sense and antisense DMPK RNA foci accumulate in DM1 tissues during development. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137620"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.celrep.2015.07.029","article-title":"MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain","volume":"12","author":"Goodwin","year":"2015","journal-title":"Cell Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.1093\/nar\/gku767","article-title":"MBNL proteins and their target RNAs, interaction and splicing regulation","volume":"42","author":"Konieczny","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/ncomms3044","article-title":"Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules","volume":"4","author":"Tran","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Mart\u00ednez, A., Soblechero-Mart\u00edn, P., de-la-Puente-Ovejero, L., Nogales-Gadea, G., and Arechavala-Gomeza, V. (2020). An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I. Genes, 11.","DOI":"10.3390\/genes11091109"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nmd.2017.10.007","article-title":"Mitochondrial dysfunction in myotonic dystrophy type 1","volume":"28","author":"Gramegna","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.18632\/aging.103022","article-title":"Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin","volume":"12","author":"Matheu","year":"2020","journal-title":"Aging"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kajdasz, A., Niewiadomska, D., Sekrecki, M., and Sobczak, K. (2022). Distribution of alternative untranslated regions within the mRNA of the CELF1 splicing factor affects its expression. Sci. Rep., 12.","DOI":"10.1038\/s41598-021-03901-9"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Timchenko, L. (2020). Correction of RNA-Binding Protein CUGBP1 and GSK3\u03b2 Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010094"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4161\/rna.28799","article-title":"Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1","volume":"11","author":"Wojciechowska","year":"2014","journal-title":"RNA Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased Steady-State Levels of CUGBP1 in Myotonic Dystrophy 1 Are Due to PKC-Mediated Hyperphosphorylation","volume":"28","author":"Wang","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1101\/gr.184390.114","article-title":"Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins","volume":"25","author":"Wang","year":"2015","journal-title":"Genome Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1093\/nar\/gkp681","article-title":"MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1","volume":"37","author":"Kino","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Tahraoui-Bories, J., M\u00e9rien, A., Gonz\u00e1lez-Barriga, A., Lain\u00e9, J., Leteur, C., Polv\u00e8che, H., Carteron, A., De Lamotte, J.D., Nicoleau, C., and Polentes, J. (2023). MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1. Neuropathol. Appl. Neurobiol., 49.","DOI":"10.1111\/nan.12876"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1126\/science.1088679","article-title":"RNA Leaching of Transcription Factors Disrupts Transcription in Myotonic Dystrophy","volume":"303","author":"Ebralidze","year":"2004","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Imbriano, C., and Molinari, S. (2018). Alternative Splicing of Transcription Factors Genes in Muscle Physiology and Pathology. Genes, 9.","DOI":"10.3390\/genes9020107"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/hmg\/ddp058","article-title":"Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy","volume":"18","author":"Osborne","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_79","unstructured":"Maga\u00f1a, J.J., Su\u00e1rez-S\u00e1nchez, R., Leyva-Garc\u00eda, N., Cisneros, B., and Hern\u00e1ndez-Hern\u00e1ndez, O. (2012). Myotonic Dystrophy Protein Kinase: Structure, Function and Its Possible Role in the Pathogenesis of Myotonic Dystrophy Type 1. Adv. Protein Kinases, 213\u2013242."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nmd.2010.11.012","article-title":"Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1","volume":"21","author":"Perbellini","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Costa, A., Cruz, A.C., Martins, F., and Rebelo, S. (2023). Protein Phosphorylation Alterations in Myotonic Dystrophy Type 1: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043091"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1074\/jbc.M112.436915","article-title":"Sarcolipin Protein Interaction with Sarco(endo)plasmic Reticulum Ca2+ATPase (SERCA) Is Distinct from Phospholamban Protein, and Only Sarcolipin Can Promote Uncoupling of the SERCA Pump","volume":"288","author":"Sahoo","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yjmcc.2015.12.030","article-title":"Phospholamban and sarcolipin: Are they functionally redundant or distinct regulators of the Sarco(Endo)Plasmic Reticulum Calcium ATPase?","volume":"91","author":"Shaikh","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nature13124","article-title":"C9orf72 nucleotide repeat structures initiate molecular cascades of disease","volume":"507","author":"Haeusler","year":"2014","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e101112","DOI":"10.15252\/embj.2018101112","article-title":"RNA toxicity in non-coding repeat expansion disorders","volume":"39","author":"Swinnen","year":"2020","journal-title":"EMBO J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1073\/pnas.1013343108","article-title":"Non-ATG\u2013initiated translation directed by microsatellite expansions","volume":"108","author":"Zu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41374-019-0241-x","article-title":"Repeat-associated non-AUG (RAN) translation: Insights from pathology","volume":"99","author":"Ranum","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Koehorst, E., N\u00fa\u00f1ez-Manch\u00f3n, J., Ballester-L\u00f3pez, A., Almendrote, M., Lucente, G., Arbex, A., Chojnacki, J., V\u00e1zquez-Manrique, R.P., G\u00f3mez-Escribano, A.P., and Pintos-Morell, G. (2021). Characterization of RAN translation and antisense transcription in primary cell cultures of patients with myotonic dystrophy type 1. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235520"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.celrep.2013.12.025","article-title":"The Mef2 Transcription Network Is Disrupted in Myotonic Dystrophy Heart Tissue, Dramatically Altering miRNA and mRNA Expression","volume":"6","author":"Kalsotra","year":"2014","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2044-5040-1-19","article-title":"Role of TGF-\u03b2 signaling in inherited and acquired myopathies","volume":"1","author":"Burks","year":"2011","journal-title":"Skelet. Muscle"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e127356","DOI":"10.1172\/jci.insight.127356","article-title":"ERK1\/2 signaling induces skeletal muscle slow fiber-type switching and reduces muscular dystrophy disease severity","volume":"4","author":"Boyer","year":"2019","journal-title":"JCI Insight"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.biocel.2010.08.010","article-title":"Altered signal transduction pathways and induction of autophagy in human myotonic dystrophy type 1 myoblasts","volume":"42","author":"Beffy","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1172\/JCI89616","article-title":"Targeting deregulated AMPK\/mTORC1 pathways improves muscle function in myotonic dystrophy type I","volume":"127","author":"Brockhoff","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Braun, M., Shoshani, S., and Tabach, Y. (2022). Transcriptome changes in DM1 patients\u2019 tissues are governed by the RNA interference pathway. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.955753"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Todorow, V., Hintze, S., Schoser, B., and Meinke, P. (2023). Nuclear envelope transmembrane proteins involved in genome organization are misregulated in myotonic dystrophy type 1 muscle. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1007331"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Meinke, P., Hintze, S., Limmer, S., and Schoser, B. (2018). Myotonic Dystrophy\u2014A Progeroid Disease?. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00601"},{"key":"ref_97","first-page":"17-0143","article-title":"Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency","volume":"2018","author":"Takeshima","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Viegas, D., Pereira, C.D., Martins, F., Mateus, T., da Cruz e Silva, O.A.B., Herdeiro, M.T., and Rebelo, S. (2022). Nuclear Envelope Alterations in Myotonic Dystrophy Type 1 Patient-Derived Fibroblasts. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010522"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"40296","DOI":"10.1074\/jbc.M111.241455","article-title":"Myotonic Dystrophy Protein Kinase Is Critical for Nuclear Envelope Integrity","volume":"286","author":"Harmon","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/WCO.0000000000000359","article-title":"The increasing relevance of nuclear envelope myopathies","volume":"29","author":"Meinke","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40035-020-00205-2","article-title":"Nucleo\u2013cytoplasmic transport defects and protein aggregates in neurodegeneration","volume":"9","author":"Bitetto","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/genes5030767","article-title":"Regulation of mRNA Trafficking by Nuclear Pore Complexes","volume":"5","author":"Bonnet","year":"2014","journal-title":"Genes"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1365-2443.2007.01112.x","article-title":"Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles","volume":"12","author":"Holt","year":"2007","journal-title":"Genes Cells"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders\u2014A step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Heher, P., Ganassi, M., Weidinger, A., Engquist, E.N., Pruller, J., Nguyen, T.H., Tassin, A., Decl\u00e8ves, A.-E., Mamchaoui, K., and Banerji, C.R.S. (2022). Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target. Redox Biol., 51.","DOI":"10.1016\/j.redox.2022.102251"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/10715760500138932","article-title":"Oxidative stress in myotonic dystrophy type 1","volume":"39","author":"Toscano","year":"2005","journal-title":"Free Radic. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.52.1.170","article-title":"Linkage of proximal myotonic myopathy to chromosome 3q","volume":"52","author":"Ricker","year":"1999","journal-title":"Neurology"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Fujino, H., Saito, T., Takahashi, M.P., Takada, H., Nakayama, T., Imura, O., and Matsumura, T. (2022). Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02581-w"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ejhpharm-2015-000839","article-title":"A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia","volume":"23","author":"Shum","year":"2016","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/WNL.0000000000011002","article-title":"Mexiletine in Myotonic Dystrophy Type 1","volume":"96","author":"Heatwole","year":"2021","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"ref_113","first-page":"126","article-title":"Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy","volume":"23","author":"McBride","year":"2022","journal-title":"RCM"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/09638288.2017.1292322","article-title":"Clinical features of children and adults with a muscular dystrophy using powered indoor\/outdoor wheelchairs: Disease features, comorbidities and complications of disability","volume":"40","author":"Frank","year":"2018","journal-title":"Disabil. Rehabil."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Tripathi, A., and Miliken, A. (2023). Myotonic Dystrophy Type 1: A Comprehensive Literary Review. J. Stud. Res., 12.","DOI":"10.47611\/jsrhs.v12i4.5584"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Roussel, M.-P., Morin, M., Gagnon, C., and Duchesne, E. (2019). What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review. BMC Musculoskelet. Disord., 20.","DOI":"10.1186\/s12891-019-2458-7"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archneurol.2010.227","article-title":"Open-label trial of recombinant human insulin-like growth factor 1\/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1","volume":"68","author":"Heatwole","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/01.wnl.0000324257.35759.40","article-title":"Dehydroepiandrosterone for myotonic dystrophy type 1","volume":"71","author":"Devillers","year":"2008","journal-title":"Neurology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mus.10527","article-title":"Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1","volume":"29","author":"Tarnopolsky","year":"2004","journal-title":"Muscle Nerve"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00415-002-0923-x","article-title":"Creatine monohydrate in myotonic dystrophy: A double-blind, placebo-controlled clinical study","volume":"249","author":"Walter","year":"2002","journal-title":"J. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ahsan, M., Garneau, L., and Aguer, C. (2022). The bidirectional relationship between AMPK pathway activation and myokine secretion in skeletal muscle: How it affects energy metabolism. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.1040809"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.molmed.2022.04.004","article-title":"Combinatorial therapies for rescuing myotonic dystrophy type 1 skeletal muscle defects","volume":"28","author":"Jasmin","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_123","first-page":"s00441779295","article-title":"Rehabilitation interventions targeting the activity and participation of patient with neuromuscular diseases: What do we know? A systematic review","volume":"82","author":"Silva","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e160229","DOI":"10.1172\/JCI160229","article-title":"Benefits of aerobic exercise in myotonic dystrophy type 1","volume":"132","author":"Mackenzie","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e156125","DOI":"10.1172\/JCI156125","article-title":"Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes","volume":"132","author":"Mikhail","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/jnnp.2006.099051","article-title":"Myotonic dystrophy: Practical issues relating to assessment of strength","volume":"77","author":"Whittaker","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nmd.2021.09.014","article-title":"Outcome measures frequently used to assess muscle strength in patients with myotonic dystrophy type 1: A systematic review","volume":"32","author":"Mateus","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Hartog, L., Zhao, J., Reynolds, J., Brokamp, G., Vilson, F., Arnold, W.D., and LoRusso, S. (2021). Factors Influencing the Severity and Progression of Respiratory Muscle Dysfunction in Myotonic Dystrophy Type 1. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.658532"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.resp.2014.01.006","article-title":"Supine changes in lung function correlate with chronic respiratory failure in myotonic dystrophy patients","volume":"193","author":"Poussel","year":"2014","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.nmd.2015.01.011","article-title":"207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: Management and implications for research, 27\u201329 June 2014, Naarden, The Netherlands","volume":"25","author":"Sansone","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00415-014-7526-1","article-title":"Diagnosis of muscle diseases presenting with early respiratory failure","volume":"262","author":"Pfeffer","year":"2015","journal-title":"J. Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3233\/JND-160191","article-title":"Sleepiness and sleep-related breathing disorders in myotonic dystrophy and responses to treatment: A prospective cohort study","volume":"3","author":"West","year":"2016","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.mcp.0000245704.92311.1e","article-title":"Sleep disorders in neuromuscular diseases","volume":"12","author":"Dhand","year":"2006","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.sleep.2020.12.036","article-title":"Altered REM sleep architecture in patients with Myotonic dystrophy type 1: Is related to sleep apnea?","volume":"79","author":"Seshagiri","year":"2021","journal-title":"Sleep Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.117.029400","article-title":"Sleep apnea and cardiovascular disease: Lessons from recent trials and need for team science","volume":"136","author":"Drager","year":"2017","journal-title":"Circulation"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e30518","DOI":"10.1097\/MD.0000000000030518","article-title":"Pneumonia and de novo atrial fibrillation in a patient with myotonic dystrophy type 1: A case report","volume":"101","year":"2022","journal-title":"Medicine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11055-024-01565-2","article-title":"Sleep Disorders and Fatigue in Patients with Different Forms of Myotonic Dystrophy Type 1","volume":"54","author":"Erokhina","year":"2024","journal-title":"Neurosci. Behav. Physiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"zsad280","DOI":"10.1093\/sleep\/zsad280","article-title":"Polysomnographic findings of myotonic dystrophy type 1\/type 2: Evidence from case\u2013control studies","volume":"47","author":"Zhang","year":"2024","journal-title":"Sleep"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1159\/000515453","article-title":"Noninvasive home mechanical ventilation in adult myotonic dystrophy type 1: A systematic review","volume":"100","author":"Vosse","year":"2021","journal-title":"Respiration"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.nmd.2023.08.004","article-title":"Role of respiratory characteristics in treatment adherence with noninvasive home mechanical ventilation in myotonic dystrophy type 1, a retrospective study","volume":"33","author":"Vosse","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000505634","article-title":"Consensus-based care recommendations for pulmonologists treating adults with myotonic dystrophy type 1","volume":"99","author":"Boentert","year":"2020","journal-title":"Respiration"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/mus.26866","article-title":"Sleep disorders in myotonic dystrophies","volume":"62","author":"Subramony","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_144","unstructured":"(2020, November 09). Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients with Myotonic Dystrophy Type 1, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04634682."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.clinthera.2012.03.060","article-title":"Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: A 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial","volume":"34","author":"Puymirat","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/heart.88.6.665","article-title":"Myotonic dystrophy and the heart","volume":"88","author":"Pelargonio","year":"2002","journal-title":"Heart"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Russo, V., Antonini, G., Massa, R., Casali, C., Mauriello, A., Martino, A.M., Marconi, R., Garibaldi, M., Franciosa, P., and Zecchin, M. (2024). Comprehensive Cardiovascular Management of Myotonic Dystrophy Type 1 Patients: A Report from the Italian Neuro-Cardiology Network. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.20944\/preprints202401.0263.v1"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.08.037","article-title":"Cardiac manifestations of myotonic dystrophy type 1","volume":"160","author":"Petri","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Russo, V., Capolongo, A., Bottino, R., Carbone, A., Palladino, A., Liccardo, B., Nigro, G., Marchel, M., Golino, P., and D\u2019Andrea, A. (2023). Echocardiographic Features of Cardiac Involvement in Myotonic Dystrophy 1: Prevalence and Prognostic Value. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051947"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nmd.2021.01.002","article-title":"Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review","volume":"31","author":"Russo","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.tcm.2017.12.006","article-title":"ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies","volume":"28","author":"Russo","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_152","first-page":"1148","article-title":"Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: The predictive role of programmed ventricular stimulation","volume":"24","author":"Russo","year":"2022","journal-title":"EP Eur."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijcard.2014.03.088","article-title":"High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: A cross-sectional study","volume":"174","author":"Petri","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"132070","DOI":"10.1016\/j.ijcard.2024.132070","article-title":"Natural history of cardiac involvement in myotonic dystrophy type 1\u2014Emphasis on the need for lifelong follow-up","volume":"406","author":"Petri","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e014006","DOI":"10.1161\/JAHA.119.014006","article-title":"Clinical Care Recommendations for Cardiologists Treating Adults with Myotonic Dystrophy","volume":"9","author":"McNally","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12968-021-00812-6","article-title":"Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: A cardiovascular magnetic resonance follow-up study","volume":"23","author":"Blaszczyk","year":"2021","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.19102\/icrm.2018.090103","article-title":"The use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death: A focus on congenital heart disease and inherited arrhythmia syndromes","volume":"9","author":"Goldstein","year":"2018","journal-title":"J. Innov. Card. Rhythm Manag."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Leong, A.M., Arnold, A.D., and Whinnett, Z.I. (2024). Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11030092"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.hrthm.2018.03.008","article-title":"Effect of dual-chamber minimal ventricular pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: A prospective, randomized, single-blind, crossover study","volume":"15","author":"Russo","year":"2018","journal-title":"Heart Rhythm."},{"key":"ref_160","first-page":"1375","article-title":"Broad antiarrhythmic effect of mexiletine in different arrhythmia models","volume":"20","author":"Frommeyer","year":"2018","journal-title":"EP Eur."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.acvd.2024.03.001","article-title":"Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy","volume":"117","author":"Wahbi","year":"2024","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jacc.2012.11.007","article-title":"2012 ACCF\/AHA\/HRS Focused Update Incorporated into the ACCF\/AHA\/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"61","author":"Tracy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.2012.346","article-title":"Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease","volume":"307","author":"Wahbi","year":"2012","journal-title":"JAMA"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.csbj.2024.05.009","article-title":"Disturbance of the human gut microbiota in patients with Myotonic Dystrophy type 1","volume":"23","author":"Mahdavi","year":"2024","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"14779","DOI":"10.3390\/ijms232314779","article-title":"Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2","volume":"23","author":"Peterson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0000000000004420","article-title":"High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2","volume":"89","author":"Hilbert","year":"2017","journal-title":"Neurology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00455-013-9458-9","article-title":"Oral Motor Movements and Swallowing in Patients with Myotonic Dystrophy Type 1","volume":"28","author":"Ercolin","year":"2013","journal-title":"Dysphagia"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.nmd.2022.01.008","article-title":"Genitourinary and lower gastrointestinal conditions in patients with myotonic dystrophy type 1: A systematic review of evidence and implications for clinical practice","volume":"32","author":"Gagnon","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nmd.2008.05.010","article-title":"Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2","volume":"18","author":"Tieleman","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02427560","article-title":"Positive correlation of CTG expansion and pharyngoesophageal alterations in myotonic dystrophy patients","volume":"19","author":"Marcon","year":"1998","journal-title":"Ital. J. Neurol. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13238-020-00814-7","article-title":"The role of the gut microbiome and its metabolites in metabolic diseases","volume":"12","author":"Wu","year":"2021","journal-title":"Protein Cell"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5056\/jnm20149","article-title":"Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders","volume":"27","author":"Singh","year":"2021","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2020.11.001","article-title":"Dysphagia in adult myopathies","volume":"31","author":"Argov","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_174","first-page":"CD004303","article-title":"Interventions for dysphagia in long-term, progressive muscle disease","volume":"2016","author":"Jones","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00455-013-9510-9","article-title":"Oropharyngeal dysphagia in myotonic dystrophy type 1: A systematic review","volume":"29","author":"Pilz","year":"2014","journal-title":"Dysphagia"},{"key":"ref_176","first-page":"141","article-title":"Silent dysphagia in two patients with Steinert disease and recurrent respiratory exacerbations","volume":"39","author":"Annunziata","year":"2020","journal-title":"Acta Myol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5409\/wjcp.v12.i4.197","article-title":"Gastrointestinal and nutritional care in pediatric neuromuscular disorders","volume":"12","author":"Dipasquale","year":"2023","journal-title":"World J. Clin. Pediatr."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3748\/wjg.v12.i12.1821","article-title":"Gastrointestinal manifestations in myotonic muscular dystrophy","volume":"12","author":"Bellini","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nmd.2023.12.011","article-title":"Impact of gastrointestinal and urological symptoms in children with myotonic dystrophy type 1","volume":"35","author":"Maagdenberg","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Rossi, S., and Silvestri, G. (2023). Fluid Biomarkers of Central Nervous System (CNS) Involvement in Myotonic Dystrophy Type 1 (DM1). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032204"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbadis.2011.03.010","article-title":"Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing","volume":"1812","author":"Dhaenens","year":"2011","journal-title":"Biochim. Biophys. Acta BBA-Mol. Basis Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"fcac111","DOI":"10.1093\/braincomms\/fcac111","article-title":"Unravelling the impact of frontal lobe impairment for social dysfunction in myotonic dystrophy type 1","volume":"4","author":"Morin","year":"2022","journal-title":"Brain Commun."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Simoncini, C., Spadoni, G., Lai, E., Santoni, L., Angelini, C., Ricci, G., and Siciliano, G. (2020). Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00624"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mus.23478","article-title":"Fatigue and daytime sleepiness scale in myotonic dystrophy type 1","volume":"47","author":"Hermans","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1474-4422(18)30203-5","article-title":"Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: A multicentre, single-blind, randomised trial","volume":"17","author":"Okkersen","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2147\/OPTH.S372633","article-title":"Ocular features and clinical approach to cataract and corneal refractive surgery in patients with myotonic dystrophy","volume":"16","author":"Moshirfar","year":"2022","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"ref_187","first-page":"86","article-title":"Cataract surgery in patients with Fuchs\u2019 endothelial corneal dystrophy","volume":"31","author":"Kaup","year":"2019","journal-title":"Community Eye Health"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1167\/iovs.17-22350","article-title":"Fuchs\u2019 Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy","volume":"58","author":"Mootha","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/s41433-018-0161-9","article-title":"Christmas tree cataract and myotonic dystrophy type 1","volume":"32","author":"Pagoulatos","year":"2018","journal-title":"Eye"},{"key":"ref_190","unstructured":"Nizami, A.A., Gurnani, B., Gulani, A.C., and Redmond, S.B. (2024). Cataract (Nursing). StatPearls, StatPearls Publishing."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00415-013-7141-6","article-title":"Epiretinal membrane: A treatable cause of visual disability in myotonic dystrophy type 1","volume":"261","author":"Kersten","year":"2014","journal-title":"J. Neurol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Takada, H., Matsumura, T., Shimamura, H., Matsui, M., Kon, S., Fukumoto, A., Kubota, T., Yoshida, K., Iwahashi, H., and Takahashi, M.P. (2024). Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175252"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-7-11","article-title":"Endocrine manifestations related to inherited metabolic diseases in adults","volume":"7","author":"Vantyghem","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40618-019-01156-w","article-title":"Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: A retrospective, case\u2013control study","volume":"43","author":"Spaziani","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Vaidya, R.A., Desai, S., Moitra, P., Salis, S., Agashe, S., Battalwar, R., Mehta, A., Madan, J., Kalita, S., and Udipi, S.A. (2023). Hyperinsulinemia: An early biomarker of metabolic dysfunction. Front. Clin. Diabetes Healthc., 4.","DOI":"10.3389\/fcdhc.2023.1159664"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2021). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S17\u2013S38.","DOI":"10.2337\/dc22-S002"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Puga, M., Saenz-Anto\u00f1anzas, A., Matheu, A., and L\u00f3pez de Munain, A. (2022). Targeting Myotonic Dystrophy Type 1 with Metformin. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052901"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.tips.2020.09.001","article-title":"Metformin and Systemic Metabolism","volume":"41","author":"He","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"104087","DOI":"10.1016\/j.drudis.2024.104087","article-title":"Targeting neuroinflammation in distal symmetrical polyneuropathy in diabetes","volume":"29","author":"Chong","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jns.2013.06.008","article-title":"Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies","volume":"331","author":"Passeri","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Wenninger, S., Montagnese, F., and Schoser, B. (2018). Core Clinical Phenotypes in Myotonic Dystrophies. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00303"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1559827615619159","article-title":"Lifestyle and the Prevention of Type 2 Diabetes: A Status Report","volume":"12","author":"Galaviz","year":"2018","journal-title":"Am. J. Lifestyle Med."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Mateus, T., Almeida, I., Costa, A., Viegas, D., Magalh\u00e3es, S., Martins, F., Herdeiro, M.T., da Cruz e Silva, O.A.B., Fraga, C., and Alves, I. (2021). Fourier-Transform Infrared Spectroscopy as a Discriminatory Tool for Myotonic Dystrophy Type 1 Metabolism: A Pilot Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18073800"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4111\/kju.2012.53.2.134","article-title":"Myotonic Dystrophy Type 1 Presenting as Male Infertility","volume":"53","author":"Kim","year":"2012","journal-title":"Korean J. Urol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.rbmo.2010.02.003","article-title":"Myotonic dystrophy type 1 and PGD: Ovarian stimulation response and correlation analysis between ovarian reserve and genotype","volume":"20","author":"Dechanet","year":"2010","journal-title":"Reprod. Biomed. Online"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10815-007-9193-y","article-title":"Response to controlled ovarian stimulation and oocyte quality in women with myotonic dystrophy type I","volume":"25","author":"Sahu","year":"2008","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.rbmo.2014.03.013","article-title":"Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy","volume":"29","author":"Srebnik","year":"2014","journal-title":"Reprod. Biomed. Online"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/humrep\/dei310","article-title":"Myotonic dystrophy: Does it affect ovarian follicular status and responsiveness to controlled ovarian stimulation?","volume":"21","author":"Feyereisen","year":"2006","journal-title":"Hum. Reprod."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.fertnstert.2021.07.612","article-title":"High Mitochondrial Dna Replication In Embryos Derived From Myotonic Dystrophy 1 Female","volume":"116","author":"Ijuin","year":"2021","journal-title":"Fertil. Steril."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11940-016-0434-1","article-title":"Myotonic dystrophy type 1 management and therapeutics","volume":"18","author":"Smith","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejogrb.2012.02.020","article-title":"Pregnancy course and outcome in women with hereditary neuromuscular disorders: Comparison of obstetric risks in 178 patients","volume":"162","author":"Awater","year":"2012","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_212","first-page":"359","article-title":"Neurologic disease with pregnancy and considerations for the obstetric anesthesiologist","volume":"38","author":"Hopkins","year":"2014","journal-title":"Spec. Top. Obstet. Anesth."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3233\/JND-150095","article-title":"The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study","volume":"2","author":"Johnson","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10815-010-9392-9","article-title":"The reproductive outcome of female patients with myotonic dystrophy type 1 (DM1) undergoing PGD is not affected by the size of the expanded CTG repeat tract","volume":"27","author":"Verpoest","year":"2010","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dmcn.15332","article-title":"Assisted reproductive technology: Short- and long-term outcomes","volume":"65","author":"Graham","year":"2023","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1753495X18824238","article-title":"Myotonic disorders and pregnancy","volume":"13","author":"Morton","year":"2020","journal-title":"Obstet. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/uog.3859","article-title":"Congenital myotonic dystrophy: Prenatal ultrasound findings and pregnancy outcome","volume":"29","author":"Zaki","year":"2007","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1055\/s-0033-1360163","article-title":"Polyhydramnios: Causes, Diagnosis and Therapy","volume":"73","author":"Hamza","year":"2013","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Huri, M., Di Tommaso, M., and Seravalli, V. (2023). Amniotic Fluid Disorders: From Prenatal Management to Neonatal Outcomes. Children, 10.","DOI":"10.3390\/children10030561"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nmd.2015.02.013","article-title":"Skin features in myotonic dystrophy type 1: An observational study","volume":"25","author":"Campanati","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nmd.2016.11.004","article-title":"Cutaneous features of myotonic dystrophy types 1 and 2: Implication of premature aging and vitamin D homeostasis","volume":"27","author":"Campione","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1054\/bjps.1998.3036","article-title":"Multiple pilomatrixomata and myotonic dystrophy: A familial association","volume":"52","author":"Geh","year":"1999","journal-title":"Br. J. Plast. Surg."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-4632.2004.02583.x","article-title":"Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1","volume":"45","author":"Saponaro","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"R\u00fcbben, A., Wahl, R.U., Eggermann, T., Dahl, E., Ortiz-Br\u00fcchle, N., and Cacchi, C. (2020). Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype. PLoS ONE, 15.","DOI":"10.1101\/844647"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"103489","DOI":"10.1016\/j.drudis.2023.103489","article-title":"The myotonic dystrophy type 1 drug development pipeline: 2022 edition","volume":"28","author":"Artero","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00018-024-05229-9","article-title":"Molecular mechanisms and therapeutic strategies for neuromuscular diseases","volume":"81","author":"Zambon","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_227","first-page":"e35077","article-title":"Clinical Trials and Clinical Research: A Comprehensive Review","volume":"15","author":"Kandi","year":"2023","journal-title":"Cureus"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"B\u00e9renger-Currias, N., Martinat, C., and Baghdoyan, S. (2023). Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1. Cells, 12.","DOI":"10.3390\/cells12040571"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/hum.2012.212","article-title":"Antisense Oligonucleotides: Rising Stars in Eliminating RNA Toxicity in Myotonic Dystrophy","volume":"24","author":"Gao","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/nar\/gkaa007","article-title":"AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1","volume":"48","author":"Konieczny","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/nar\/gkab022","article-title":"Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy","volume":"49","author":"Tanner","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"12055","DOI":"10.1093\/nar\/gkae774","article-title":"MBNL splicing factors regulate the microtranscriptome of skeletal muscles","volume":"52","author":"Piasecka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12964-025-02102-5","article-title":"Functions of the Muscleblind-like protein family and their role in disease","volume":"23","author":"Zhou","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1042\/BST0371281","article-title":"Pathogenic mechanisms of myotonic dystrophy","volume":"37","author":"Lee","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"e26555","DOI":"10.4161\/rdis.26555","article-title":"GSK3\u03b2 is a new therapeutic target for myotonic dystrophy type 1","volume":"1","author":"Wei","year":"2013","journal-title":"Rare Dis."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng704","article-title":"Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy","volume":"29","author":"Savkur","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Nieuwenhuis, S., Okkersen, K., Widomska, J., Blom, P., \u2019t Hoen, P.A.C., van Engelen, B., and Glennon, J.C. (2019). Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01229"},{"key":"ref_238","first-page":"705","article-title":"Myotonic Dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Myopathies"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/01.WNL.0000054481.84978.F9","article-title":"Myotonic dystrophy type 2","volume":"60","author":"Day","year":"2003","journal-title":"Neurology"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1038\/mtna.2015.35","article-title":"In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin","volume":"4","author":"Laustriat","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.drudis.2018.08.004","article-title":"RNA-mediated therapies in myotonic dystrophy","volume":"23","author":"Overby","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Stoodley, J., Vallejo-Bedia, F., Seone-Miraz, D., Debasa-Mouce, M., Wood, M.J.A., and Varela, M.A. (2023). Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032697"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Timchenko, L. (2022). Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810491"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Morat\u00f3, M., Brook, J.D., and Wojciechowska, M. (2018). Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00349"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"e00155-19","DOI":"10.1128\/MCB.00155-19","article-title":"Correction of Glycogen Synthase Kinase 3\u03b2 in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice","volume":"39","author":"Wang","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1172\/JCI64081","article-title":"GSK3\u03b2 mediates muscle pathology in myotonic dystrophy","volume":"122","author":"Jones","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Liu, J., Guo, Z.-N., Yan, X.-L., Yang, Y., and Huang, S. (2021). Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.755392"},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Lutz, M., Levanti, M., Karns, R., Gourdon, G., Lindquist, D., Timchenko, N.A., and Timchenko, L. (2023). Therapeutic Targeting of the GSK3\u03b2-CUGBP1 Pathway in Myotonic Dystrophy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310650"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2020.08.001","article-title":"A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1)","volume":"112","author":"Horrigan","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"102338","DOI":"10.1016\/j.omtn.2024.102338","article-title":"Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1","volume":"35","author":"Hicks","year":"2024","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.eclinm.2023.102390","article-title":"Erythromycin for myotonic dystrophy type 1: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"67","author":"Nakamori","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/acn3.271","article-title":"Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy","volume":"3","author":"Nakamori","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Platon, V.-M., Dragoi, B., and Marin, L. (2022). Erythromycin Formulations\u2014A Journey to Advanced Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102180"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Sanjurjo-Rodr\u00edguez, C., Castro-Vi\u00f1uelas, R., Pi\u00f1eiro-Ramil, M., Rodr\u00edguez-Fern\u00e1ndez, S., Fuentes-Boquete, I., Blanco, F.J., and D\u00edaz-Prado, S. (2020). Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176124"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(73)92270-8","article-title":"Treatment of ventricular arrhythmias with mexiletine (k\u00f61173)","volume":"302","author":"Talbot","year":"1973","journal-title":"Lancet"},{"key":"ref_256","unstructured":"(2019, June 17). Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults with Myotonic Dystrophy Type 1, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03959189."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1038\/s41467-023-39663-3","article-title":"Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1","volume":"14","author":"Conte","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_258","unstructured":"(2016, July 20). A Single-Blind, Phase 2 Study to Evaluate The Safety and Efficacy of Tideglusib 400mg or 1000mg for the Treatment of Adolescent and Adult Congenital and Juvenile-Onset Myotonic Dystrophy , Available online: https:\/\/clinicaltrials.gov\/study\/NCT02858908."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.nmd.2023.07.030","article-title":"P49 The efficacy and safety of Tideglusib in a randomized, placebo-controlled, double blind study in children and adolescents with congenital myotonic dystrophy (REACH CDM study)","volume":"33","author":"Horrigan","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cortex.2023.07.008","article-title":"Characterization of theory of mind performance in patients with myotonic dystrophy type 1","volume":"168","author":"Davion","year":"2023","journal-title":"Cortex"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/mi.2023.106","article-title":"Undiagnosed myotonic dystrophy: A case report and literature review","volume":"3","author":"Yamada","year":"2023","journal-title":"Med. Int."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: A randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"key":"ref_263","unstructured":"(2024, March 01). Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert\u2019s Disease). A Phase III, Prospective, Multicentre, Randomized, Double-Blind Controlled Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05532813."},{"key":"ref_264","unstructured":"(2021, September 03). An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic Disorders, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04624750."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1212\/CPJ.0000000000001073","article-title":"Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2","volume":"11","author":"Mousele","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"ref_266","unstructured":"(2021, November 05). Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed the MEX-NM-301 Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04622553."},{"key":"ref_267","unstructured":"(2020, December 17). An Observational Study to Describe the Long-Term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients with Non-dystrophic Myotonic Disorders, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04616807."},{"key":"ref_268","unstructured":"(2021, September 03). A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 [The MIND Study], Available online: https:\/\/clinicaltrials.gov\/study\/NCT04700046."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1212\/WNL.96.15_supplement.2834","article-title":"Results of Double-blind, Placebo-controlled, Dose Range Finding, Crossover Study of Single Day Administration of ERX-963 (IV Flumazenil) in Adults with Myotonic Dystrophy Type 1 (2834)","volume":"96","author":"Sampson","year":"2021","journal-title":"Neurology"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"P5.443","DOI":"10.1212\/WNL.90.15_supplement.P5.443","article-title":"Investigation of Ranolazine as an Anti-myotonia Treatment in Myotonic Dystrophy Type 1 (P5.443)","volume":"90","author":"Lawless","year":"2018","journal-title":"Neurology"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/mus.26372","article-title":"Open-label trial of ranolazine for the treatment of paramyotonia congenita","volume":"59","author":"Lorusso","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_272","unstructured":"(2021, June 28). A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients with Myotonic Dystrophy Type 1, Followed by an Open-Label Extension, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04886518."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.drudis.2021.03.024","article-title":"Myotonic dystrophy type 1 drug development: A pipeline toward the market","volume":"26","author":"Artero","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_274","unstructured":"(2024, August 25). Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints. Press Release Presented at 20 May 2024. Available online: https:\/\/investors.dyne-tx.com\/news-releases\/news-release-details\/dyne-therapeutics-announces-new-clinical-data-achieve-trial-dyne."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.nmd.2023.07.031","article-title":"P50 A phase 1\/2 randomized, placebo-controlled, multiple ascending dose study (ACHIEVE) of DYNE-101 in individuals with myotonic dystrophy type 1 (DM1)","volume":"33","author":"Wolf","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","article-title":"Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: A multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial","volume":"22","author":"Thornton","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_277","unstructured":"(2024, May 24). A Phase 1\/2a Double-Blind, Placebo-Controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 in Male and Female Participants Aged 18 to 64 with Classic DM1, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06300307."},{"key":"ref_278","unstructured":"(2021, October 28). A Randomized, Double-Blind, Placebo-Controlled, Phase 1\/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients , Available online: https:\/\/clinicaltrials.gov\/study\/NCT05027269."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1212\/WNL.0000000000202529","article-title":"Preliminary Assessment of the Phase 1\/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA) (S48.002)","volume":"100","author":"Johnson","year":"2023","journal-title":"Neurology"},{"key":"ref_280","unstructured":"(2022, August 04). A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05479981."},{"key":"ref_281","unstructured":"(2024, May 30). A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06411288."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"104441.68","DOI":"10.1016\/j.nmd.2024.07.077","article-title":"226P Phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of myotonic dystrophy type 1: HARBOR trial design","volume":"43","author":"Fowler","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"104441.515","DOI":"10.1016\/j.nmd.2024.07.524","article-title":"440P Nonclinical data for PGN-EDODM1 demonstrated nuclear delivery, mechanistic and meaningful activity for the potential treatment of DM1","volume":"43","author":"Gilbert","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"104441.536","DOI":"10.1016\/j.nmd.2024.07.545","article-title":"461P Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 clinical trials in myotonic dystrophy type 1","volume":"43","author":"Larkindale","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_285","unstructured":"Dyke, J.V., Ai, T., and Li, X. (2024, August 24). Silencing DMPK Gene by ARO-DM1, an siRNA Therapeutic, for Type 1 Myotonic Dystrophy. Available online: https:\/\/www.mdaconference.org\/abstract-library\/silencing-dmpk-gene-by-aro-dm1-an-sirna-therapeutic-for-type-1-myotonic-dystrophy\/."},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Leckie, J., and Yokota, T. (2024). Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. Molecules, 29.","DOI":"10.20944\/preprints202405.0274.v1"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3233\/JND-200560","article-title":"Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases","volume":"8","author":"Aoki","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Ther."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"9840","DOI":"10.1093\/nar\/gkaa715","article-title":"Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity","volume":"48","author":"Liang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s43856-025-00733-w","article-title":"FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models","volume":"5","author":"Weeden","year":"2025","journal-title":"Commun. Med."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41467-018-04892-4","article-title":"miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models","volume":"9","author":"Moreno","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"109930","DOI":"10.1016\/j.isci.2024.109930","article-title":"Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity","volume":"27","author":"Juanola","year":"2024","journal-title":"iScience"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"103375","DOI":"10.1016\/j.scr.2024.103375","article-title":"Generation of three myotonic dystrophy type 1 patient iPSC lines (CBRCULi018-A, CBRCULi019-A, CBRCULi020-A) derived from lymphoblastoid cell lines for disease modelling and therapeutic research","volume":"76","author":"Pierre","year":"2024","journal-title":"Stem Cell Res."},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"De Serres-B\u00e9rard, T., Ait Benichou, S., Jauvin, D., Boutjdir, M., Puymirat, J., and Chahine, M. (2022). Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113359"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"(2024, August 24). PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights. PepGen Inc. Available online: https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-reports-second-quarter-2024-financial-results-and-recent.","DOI":"10.1016\/j.fopow.2024.08.014"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.omtn.2023.02.007","article-title":"Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics","volume":"31","author":"Maksudov","year":"2023","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.omtn.2023.06.022","article-title":"The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders","volume":"33","author":"Li","year":"2023","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_299","doi-asserted-by":"crossref","unstructured":"Almeida, C.F., Robriquet, F., Vetter, T.A., Huang, N., Neinast, R., Hernandez-Rosario, L., Rajakumar, D., Arnold, W.D., McBride, K.L., and Flanigan, K.M. (2023). Promising AAV.U7snRNAs vectors targeting DMPK improve DM1 hallmarks in patient-derived cell lines. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1181040"},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Ponomarev, A.S., Chulpanova, D.S., Yanygina, L.M., Solovyeva, V.V., and Rizvanov, A.A. (2023). Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813743"},{"key":"ref_301","unstructured":"(2024, August 26). Developing AAV-Based Genetic Medicines for Rare Neuromuscular Diseases. Available online: https:\/\/www.astellasgenetherapies.com\/our-pipeline."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2021.11.024","article-title":"Time-controlled and muscle-specific CRISPR\/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene","volume":"27","author":"Cardinali","year":"2022","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_303","doi-asserted-by":"crossref","unstructured":"Asmamaw Mengstie, M. (2022). Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.895713"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ymthe.2019.05.021","article-title":"Genome editing of expanded CTG repeats within the human DMPK gene reduces nuclear RNA foci in the muscle of DM1 mice","volume":"27","author":"Scrudato","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41551-020-00607-7","article-title":"The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1","volume":"5","author":"Batra","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41551-021-00838-2","article-title":"Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats","volume":"6","author":"Arandel","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.omtn.2022.10.023","article-title":"Sustainable recovery of MBNL activity in autoregulatory feedback loop in myotonic dystrophy","volume":"30","author":"Rogalska","year":"2022","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Rapti, K., and Grimm, D. (2021). Adeno-Associated Viruses (AAV) and Host Immunity\u2014A Race Between the Hare and the Hedgehog. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.753467"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1093\/nar\/gky548","article-title":"Efficient CRISPR\/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells","volume":"46","author":"Dastidar","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_311","doi-asserted-by":"crossref","unstructured":"Zhang, M.-L., Li, H.-B., and Jin, Y. (2024). Application and perspective of CRISPR\/Cas9 genome editing technology in human diseases modeling and gene therapy. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1364742"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.omtn.2023.05.007","article-title":"Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells","volume":"32","author":"Porquet","year":"2023","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: Why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: From concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1261\/rna.079519.122","article-title":"Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders","volume":"29","author":"Morelli","year":"2023","journal-title":"RNA"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"e17488","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike","year":"2023","journal-title":"Heliyon"},{"key":"ref_317","doi-asserted-by":"crossref","unstructured":"Yetisgin, A.A., Cetinel, S., Zuvin, M., Kosar, A., and Kutlu, O. (2020). Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules, 25.","DOI":"10.3390\/molecules25092193"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting Strategies for Tissue-Specific Drug Delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s43586-022-00100-2","article-title":"Designing clinical trials for rare diseases: Unique challenges and opportunities","volume":"2","author":"Pizzamiglio","year":"2022","journal-title":"Nat. Rev. Methods Primer"},{"key":"ref_320","doi-asserted-by":"crossref","unstructured":"Savi\u0107 Pavi\u0107evi\u0107, D., Miladinovi\u0107, J., Brku\u0161anin, M., \u0160vikovi\u0107, S., Djurica, S., Braju\u0161kovi\u0107, G., and Romac, S. (2013). Molecular Genetics and Genetic Testing in Myotonic Dystrophy Type 1. BioMed Res. Int., 2013.","DOI":"10.1155\/2013\/391821"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-016-0417-z","article-title":"Disease awareness in myotonic dystrophy type 1: An observational cross-sectional study","volume":"11","author":"Baldanzi","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/hex.13254","article-title":"Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues","volume":"24","author":"Churruca","year":"2021","journal-title":"Health Expect."},{"key":"ref_323","doi-asserted-by":"crossref","unstructured":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health Qual. Life Outcomes, 4, 79.","DOI":"10.1186\/1477-7525-4-79"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:16Z","timestamp":1760031976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":323,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115350"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115350","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}